Gemtuzumab Ozogamicin (GO) is an antibody-targeted chemotherapy agent consisting of the humanized murine CD33 antibody (clone P67.6) to which the calicheamicing1 derivative is attached via a hydrolysable bifunctional linker. GO is able to induce apoptosis in vitro in CD33-expressing cells and it has been approved in USA and in Europe as monotherapy for the treatment of elderly patients (older than 60 years) with relapsed acute myeloid leukemia (AML). GO administered as a single agent has resulted in overall response rates of about 30% in previously relapsed adults AML patients (including also with incomplete platelet recovery). Preliminary data indicate a potential role for GO also as a component of induction or consolidation regimens in adults and children. As for adverse events, veno-occlusive syndrome characterizes its tolerability profile, but GO is comparatively well tolerated by most patients.
Introduction
Acute myeloid leukemia (AML) is the most common type of acute leukemia occurring in adults. Approximately 11 000 individuals are diagnosed annually in the United States as having AML. The median age at presentation is approximately 65 years. The incidence of AML and myelodysplasia appears to be rising, particularly in patients older than 60 years (O'Donnell, 2004) . The prognosis of AML adults patients is generally poor: only 15-25% of them is alive at 5 years from diagnosis and the median survival among relapsed patients is about 3-12 months (Keating et al., 1989) . More dramatic is the situation of elderly AML that presented a percentage of patients alive after 5 years lower than 5-10%. Current standard therapy consists of induction with cytotoxic chemotherapy including an anthracycline and cytarabine (ara-c) and consolidation with cyclic intensive chemotherapy, usually high doses of ara-c (HiDARAC) (NCCN, 2002) . Unfortunately, a high percentage of patients relapses or is resistant to the induction treatment: about 10-50% of patients with newly diagnosed AML may not achieve complete remission (CR). The AML relapse may be attributable to the resistance of leukemic cells to currently available chemotherapy (Montillo et al., 1998) . The treatment of refractory/relapsed AML is a relevant problem, particularly in elderly patients, for which treatment-related morbidity and mortality contraindicate a high-dose cytotoxic chemotherapy. As well as age, duration of first CR is another important outcome predictive factor in relapsed/refractory AML (Estey, 2000) . Of note CR rate is 40-60% in patients with a 1 year or longer first remission duration, but it is only 10-15% in those with a shorter first CR (Thalhammer et al., 1996) . At present, there are no standard treatment regimens for this category of patients and a wide variety of empirical approaches have been used. Different drug combinations have been experienced (i.e. ara-c plus mitoxantrone or HiDARAC), obtaining a further CR in about 40% of patients in first relapse (range 5-80%) (Vogler et al., 1994) .
It is clear that results of conventional treatments, particularly in refractory/relapsed patients, are completely unsatisfactory. Consequently, new therapies are necessary to improve survival.
Opportunities for major therapeutic advances have come from the identification of novel targets to which specific therapy can be directed, theoretically sparing normal tissues. The development of targeted therapy with monoclonal antibodies, specifically Gemtuzumab Ozogamicin (GO; Mylotarg, Wyeth-Ayerst, St Davids, PA, USA), has provided the first such agent in the armamentarium of antileukemic drugs. chemotherapy selectively to AML cells while limiting non-hematologic toxicity (Sievers et al., 2000) . The conventional schedule of GO administration is a 2-h infusion (9 mg/m 2 ) on days 1 and 15 of treatment. GO is licensed for the treatment of elderly AML patients in first relapse as single agent. However, in the recent years various studies have tested the GO combined to other antileukemic agents also in younger or pediatric patients either at relapse or at diagnosis.
Biological characteristics and therapeutical opportunities
The CD33 antigen is a 67-kDa type I transmembrane sialoglycoprotein, a founding member of a rapidly evolving immunoglobulin superfamily subset of sialic acid binding immunoglobulin-related lectins (siglecs; siglec-3) (Crocker, 2002) . Functionally, CD33 is involved in cell-cell interactions and signalling in the hematopoietic and the immune system. CD33 is characterized by the presence of two conserved immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in the cytoplasmic region, a property that is shared with all CD33-related siglecs discovered so far. If phosphorylated upon treatment with pervanadate or anti-CD33 antibody plus a cross-linking secondary antibody, these tyrosine motifs recruit and activate Src homology-2 (SH2) domain-containing tyrosine phosphatases (SHP-1 and SHP-2). Also, cross-linking of CD33 with monoclonal antibodies on normal CD34 þ cells cultured with stem cell factor (SCF) and granulocyte macrophage colony-stimulating factor (GM-CSF) has been associated with inhibition of cell growth, suggesting a role for CD33 in the negative regulation of cell proliferation (Mingari et al., 2001) . It has been shown that expression of the protein kinase Syk in AML cells correlates with responsiveness to CD33 ligation (Balailan et al., 2003) . In the responding AML cases, CD33 ligation induces phosphorylation of Syk as well as the CD33 molecule, and the formation of a Syk/CD33 complex. Nonetheless, a proportion of Sykneg AML cases might respond to CD33 ligation by substitution of Syk with the functionally overlapping ZAP-70 protein kinase.
Approximately 90% of AML patients have myeloid blast cells that express the CD33 surface antigen (Dinndorf et al., 1986; Legrand et al., 2000) . The CD33 antigen is virtually absent on steady-state, bone marrow resident hematopoietic stem cells (HSC) and on non-hematopoietic tissues but is highly expressed on granulocyte colony-stimulating factor (G-CSF-mobilized HSCs) (Rutella et al., 2000) .
GO is composed of the humanized immunoglobulin G4 (IgG4) monoclonal antibody anti-CD33 (mAb) hP67.6, linked to N-acetyl g calicheamicin dimethyl hydrazide. Unlike the HuM195 anti-CD33 antibody, which contains a human IgG1 framework, the IgG4 component of GO (hP67.6) is not cytotoxic in vitro nor does it induce complement-mediated or antibodydependent cellular cytotoxicity.
On binding of GO to CD33, the compound is rapidly internalized (van der Velden et al., 2001) and calicheamicin, which is released inside the lysosomes because of their acidic pH, binds to DNA in the minor groove in a relatively sequence-specific manner and causes DNA double-strand breaks and cell death (Ikemoto et al., 1995) . Several mechanisms responsible for sensitivity of AML cells to GO have been described, including surface levels of CD33, binding of GO to cell surface CD33, antibody-receptor internalization, re-expression of CD33, P-glycoprotein-mediated efflux of GO (Figure 1) .
Recently, the existence of a quantitative relationship between CD33 expression levels and in vitro response to GO has been demonstrated by use of lentivirusmediated gene transfer to manipulate CD33 expression in myeloid cell lines that normally lack CD33 or have very low levels of CD33 (Walter et al., 2004) . Furthermore, disruption of the CD33 cytoplasmic ITIMs, which are crucial for the internalization of antibody bound to CD33, by introduction of point mutations not only prevents internalization of Abbound CD33, but also reduces GO-induced cytotoxicity. It must be also mentioned that efficient non-CD33-mediated GO uptake can occur via endocytosis in human CD33neg acute lymphoblastic leukemias (Jedema et al., 2004) , providing a potential rationale for the use of GO in the treatment of CD33neg malignancies with endocytic capacity.
Manipulation of the expression level of CD33 on AML blasts has been advocated as a novel therapeutic approach to improve the clinical efficacy of GO. Unfortunately, scarce information is currently available on the regulation of CD33 expression on both normal and malignant cells. Preliminary in vitro studies suggest that G-CSF, GM-CSF, interferon-a, interleukin (IL)-3 and IL-6 may modestly increase CD33 expression on the surface of CD34 þ CD33 þ blast cells (Sivaraman et al., 2002) . Recently, we showed that in vivo priming with G-CSF in elderly patients with AML might be associated with an increase in the percentage of AML blasts expressing the CD33 antigen (Leone et al., 2004) , raising the possibility that augmented CD33 expression in vivo might translate into better clinical responses. Theoretically, Gemtuzumab Ozogamicin and acute myeloid leukemia L Pagano et al the combination of myeloid growth factors and GO might also enhance drug sensitivity through mechanisms that are independent of a cytokine effect on surface CD33 expression, for example, stimulation of cell proliferation or reversal of GO resistance at the molecular level.
The in vitro response of AML cell lines to GO has been shown to fall into three groups (Amico et al., 2003) : cells that become blocked in the G2 phase of cell cycle but do not go into apoptosis (THP-1); those that are blocked in G2 but rapidly go into apoptosis (HL-60 and NB-4), and, finally, cells resistant to even high doses of GO (KG-1). Furthermore, it has been shown that apoptosis involves caspase 3 activation and that G2 arrest correlates with phosphorylation of ataxia-telangiectasia mutated/ataxiatelangiectasia-related (ATM/ATR)-Chk1/Chk2 kinases, but not with induction of the other major players in both G1 and G2 arrest following DNA damage, namely, p53 and p21.
We recently investigated whether the in vitro exposure to G-CSF sensitizes AML cell lines and primary AML blast cells to the killing effect of GO . The GO-sensitive HL-60 and NB-4 AML cell lines but not GO-insensitive K562, TF-1 and KG-1a cells, displayed enhanced cell death in response to GO after in vitro priming with G-CSF. Pretreatment with G-CSF did not affect cell cycle distribution either in GO-insensitive or in GO-sensitive AML cell lines. Also, in vitro priming with G-CSF exerted negligible effects on CD33 expression levels, suggesting that mechanisms other than activation of cell division or increase of CD33-binding sites on the cell membrane might be involved in the G-CSF-induced enhancement of GO-specific cell death. The in vitro effects of G-CSF on GO-induced cytotoxicity were also evaluated in 10 consecutive elderly patients with AML. Response to GO was heterogeneous, with half of the cases showing induction of cell death and half of the cases being refractory to the cytocidal effect of GO. As already shown with AML lines, G-CSF exerted no significant effects either on cell cycle distribution or on CD33 expression level in primary AML blast cells when compared with cultures maintained with SCF and IL-3 alone. It has been shown that AML blasts from GOrefractory patients might express the ATP-binding cassette (ABC) membrane transporter P-gp/ABCB (Pallis and Russell, 2004) , the product of the MDR gene, and possess drug efflux capacity. In our study, G-CSF exerted a dose-dependent inhibition of P-gp/ ABCB1 function in efflux-competent AML cells lines. Pgp/ABCB1 expression levels were unchanged in AML cells lines exposed to G-CSF when compared with those not treated with the cytokine, suggesting that the modulation of P-gp/ABCB1 function occurred at the functional level. Collectively, these studies demonstrate that G-CSF might sensitize AML blast cells to the killing effect of GO, and the observation that in vitro pretreatment with G-CSF might sensitize GO-resistant primary AML blast cells to the cytocydal effects of GO may deserve further investigation in a wider cohort of patients, as it might have implications for the treatment of AMLs.
Clinical experiences with GO
As already reported, GO has been approved as monotherapy in USA and in Europe for the treatment of elderly patients with relapse AML; however, better results seem to be obtained when it is administered in combination with other drugs.
GO as monotherapy
In a phase I dose-escalation study, Sievers et al. (1999) treated 40 patients with refractory or relapsed AML with GO as a single-agent with doses ranging from 0.25 to 9 mg/m 2 . Inclusion criteria were: a good performance status, a white blood cell count o30 Â 10 9 /l, and absence of renal or liver dysfunction. Eighteen patients had received prior stem cell transplant (SCT). After 1-3 doses of GO, eight patients (20%) achieved a reduction in marrow blast count to less than 5% at morphological exam. Five of these eight patients recovered neutrophil count, but only three of them achieved a normal platelet level. Those patients who achieved a CR but without recovering a platelet count greater than 100 Â 10 9 /l, were considered to have achieved CR with thrombocytopenia (CRp). Toxicities were primarily infusion-related fevers and chills, and myelosuppression. Based on these results, a three open-label, multicenter phase II trials with GO at 9 mg/m 2 dose were started (Sievers et al., 2001) . All included patients were in first relapse, with the evidence of CD33 þ AML blasts. One hundred and forty-two patients with a median age of 61 years were enrolled in these three studies. The overall response rate (including both CR and CRp) was 30% with a median time to remission of 60 days. There were not differences among patients when we stratified them for age or cytogenetic risk groups. The median relapse-free survival (RFS) for all patients achieving a remission was 5.3 months. Myelosuppression was the first side effect, but about 30% of patients developed treatment-related infections and/or increase of bilirubinemia and transaminases. Hepatic veno-occlusive disease (VOD) occurred in seven patients (3%) and was fatal in two of them.
Similarly to Sivers, the Mylotarg Study Group treated 101 patients aging 60 years or older at first relapse of AML. The CR rate was 13%, with a CRp rate of 15%. The median overall survival (OS) was 5.4 months for all patients, 14.5 months for patients who achieved a CR and 11.8 months for patients who achieved a CRp. Grade 3 or 4 toxicities included neutropenia, thrombocytopenia, infections, hyperbilirubinemia, increase of transaminases and mucositis.
GO was also used in the treatment of high-risk myelodysplastic syndrome (MDS) patients, but results were very poor. Among 26 MDS patients, none achieved a CR and toxicities included grade 3/4 infections in 11 patients and grade 3/4 hepatotoxicity in eight patients .
GO as a single agent at conventional doses was compared with HiDARAC in the treatment of AML patients at first relapse. One hundred and twenty-eight patients were enrolled in each arm. Patients treated with GO achieved a CR in the 38% of cases (increasing to 41% considering also CRp). GO treatment was characterized by a higher remission duration if the first remission duration was of 3-10 months, whereas HiDARAC resulted the most efficacious when the duration of first CR was longer than 19 months. No differences were observed if the duration of first remission was between 10 and 19 months (Leopold et al., 2003) .
The efficacy of GO as monotherapy at different doses was tested in adult, elderly and pediatric patients. In a study including eight relapsed/refractory elderly AML, GO (9 mg/m 2 ) was administered after a priming with recombinant human granulocyte colony-stimulating factor (rhG-CSF) before treatment both for increasing proportion of CD34 þ /CD33 þ positive blast cells and for sensitizing blast cells to calicheamicin. A CR was observed in four patients (50%) with a median eventfree survival of 4.7 months. It is noteworthy that VOD represented the most relevant side effect, observed in three patients (37.5%) (Leone et al., 2004) .
Similarly, Piccaluga et al. (2004a) treated 24 relapsed/ refractory elderly AML patients (median age 63 years) with standard doses (9 mg/m 2 ) of GO, administered for 2-3 doses with a 2-week interval. The CR and CRp rate was 13 and 8%, respectively, with a median RFS of 6 months. The most common non-hematological toxicities were infections and liver dysfunction, but VOD occurred in one patient only.
Recently, the Mylotarg Study Group, including USA, France, The Netherlands and Germany centres (Larson et al., 2005) , presented the results of three open-label, single arm, phase II studies. They included 277 first relapsed AML patients (median age 61 years) that received monotherapy with GO at 9 mg/m 2 in two doses separated by 2 weeks. A total of 71 patients achieved remission (26%). In particular, 35 patients (13%) achieved a CR and other 36 (13%) a CRp. The median RFS was 6.4 months for the first category and 4.5 months for the second one. As for treatment-related complications, nine patients developed an intracranial hemorrhage (3%) and eight of them died for this condition, whereas other 13 patients died for infection. Liver function abnormalities with grade 3 or 4 hyperbilirubinemia were reported in 80 patients (29%); alanine aminotransferase (ALT) or ALT abnormalities were less frequently detected (18 and 9%, respectively). A total of 16 episodes of VOD were documented (5%): it was fatal in eight patients.
The Alfa Group reported the results of a pivotal phase II study in which 57 first relapsed AML patients were treated with GO at a dose of 3 mg/m 2 on days 1, 4, 7. Fifteen patients (26%) achieved CR and other four patients CRp (7%). The median RFS was 11 months in both the group of patients, CR and CRp. No major liver toxicities were observed and the authors concluded that GO administered in fractioned doses showed an excellent efficacy/safety profile (Taksin et al., 2007) .
In the last years, GO as monotherapy was used also in induction of first remission particularly in high-risk elderly AML.
A study by GIMEMA-EORTC evaluated the efficacy of GO as single-agent treatment for frail elderly AML patients (AML-15B trial). Forty untreated patients received GO 9 mg/m 2 in two doses separated by 2 weeks. More than 50% of them aged over 75 years. A total of seven patients (four CR and three CRp) were considered responsive (17%), whereas 24 patients were resistant (60%) and other seven patients (17%) died in induction (two patients were not valuable). The median OS was 4.3 months with a 1-and 2-year survival rates of 34 and 7%. Myelosuppression occurred in the majority of patients, and the most frequently related complications were microbiologically documented infections (40%). Severe liver toxicity was observed in four cases (10%), but only one of them developed a fatal VOD. The authors stated that GO at this schedule resulted too toxic in patients aging over 75 years (Amadori et al., 2005) . Conversely, in another small pilot study by Nabhan et al. (2004) 12 patients with AML aging over 65 years were treated with GO as first induction; among 11 valuable cases, a response rate was observed in three patients (27%) with an RFS of 7.6 months. Adverse events were considered acceptable by authors: grade 3 and 4 cardiac toxicity in five patients (41%) (Nabhan et al., 2005) . In 2005, Thomas et al. (2005) reported their experience with GO in two different schedules (6 mg/m 2 on day 1; 15 or 3 mg/m 2 on days 1, 4 and 7). A total of 30 patients were treated and an overall response of 30% was obtained (nine patients). Better results were observed in younger patients (lower than 60 years). As for side effects, a high percentage of febrile neutropenia and infections was observed (63%). However, the results of this trial were very poor because of a median RFS of 3 months.
More recently the Leiden University Group reported its experience in 38 AML patients, both at diagnosis and at relapse, treated with GO at 6 and 9 mg/m 2 . A CR was observed in 12 patients, including five patients with CRp, whereas one patient achieved a PR. The best results were observed in AML at diagnosis (47% CR in newly diagnosed vs 22% in relapsed group) and in those with de novo AML (60% CR vs 22% in secondary AML; P ¼ 0.015) (Van der Heiden et al., 2006) .
The results of the main studies about GO used in monotherapy are reported in Table 1 .
Considering pediatric AML, some studies investigated the efficacy of GO in this subgroup patients. In the first report, about 15 patients with relapsed/refractory AML, eight patients showed an improvement with a reduction of bone marrow blasts count, but only one CRp was documented (Zwaan et al., 2003) . More recently, 12 multiple relapsed or refractory AML children received GO as compassionate use. Five children presented a hematological improvement with a bone marrow blastic count lower than 5% without achieving a CR. Only one patient presented a VOD that recovered after defibrotide treatment (Reinhardt et al., 2004) . In another series, 29 refractory or relapsed children received two doses of GO (separated by 2 weeks) at 6, 7.5 or 9 mg/m 2 . In 13 of them, GO administration was followed by hematopoietic stem cell transplantation (HSCT). A total of eight patients (28%) achieved overall remission without differences between resistant or relapsed disease. All of them developed a high myelosuppression, complicated by sepsis in 24% of cases. Almost all patients had transient and reversible alterations in liver function test results (aspartate aminotransferase, ALT and total bilirubin). Grade 3 and 4 elevations were observed in eight (28%) patients and VOD occurred in seven patients (Arceci et al., 2005) .
G-O combined with other chemotherapies
Other trials evaluated the efficacy of GO in combination with cytotoxic chemotherapy for treating refractory/ relapsed AML or as front-line therapy. GO was associated with different drugs in order to achieve a higher CR rate and to prolong RFS.
GO in refractory/relapsed AML In one of the first studies, GO was employed at 9 mg/m 2 combined with ara-c and topotecan (Cortes et al., 2002) . Seventeen patients with AML or advanced MDS (nine resistant and eight relapsed disease) were treated. Two patients (12%) achieved a CR. The median OS was 8.2 weeks. Liver toxicity was observed in five patients (29%) and one of them died for VOD. GO was tested in combination with ara-c, mitoxantrone and amifostine in 19 patients with either relapsed or post-MDS AML . The results were dramatic. Eight patients had treatment-related liver toxicity and three of them died for progression of this complication. Eleven of the 19 enrolled patients died for sepsis, bleeding, multiorgan failure or progressive disease.
During the following years, GO was combined with many other different drugs. It was tested in association with idarubicin and ara-c (MIA) in 14 patients with AML (four refractory and 10 relapsed). GO was administered at a dose of 6 mg/m 2 (Alvarado et al., 2003) . Six patients were responsive: three of them (21%) achieved a CR, whereas remaining three (21%) achieved a CRp. Six patients (43%) died early during the aplasia, and two patients were refractory to therapy. The median OS was 8 weeks (range 2-64 weeks). The median RFS of patients who achieved a CR or a CRp was 27 weeks (range 11-64 weeks). The treatment was associated with Gemtuzumab Ozogamicin and acute myeloid leukemia L Pagano et al myelosuppression. Grade 3 or 4 sepsis occurred in 10 patients (71%). Eight patients (57%) showed an increase of transaminases, and two of them (14%) developed hepatic VOD. In a pilot study, GO was associated to ciclosporin (CSA), ara-c and liposomal daunorubicin (MDAC) (Apostolidou et al., 2003) to treat 11 patients with refractory AML. Only one patient (9%) achieved a CR, and another one achieved a CRp. The most relevant toxicities observed were: sepsis (63%), hyperbilirubinemia, (54%), mucositis (27%) and increased transaminases levels (9%). The association of GO-CSA was employed in a larger study including also ara-c and fludarabine (MFAC) (Tsimberidou et al., 2003a) . GO was administered at a dose of 4.5 mg/m 2 in 32 patients with refractory (34%) or relapsed AML (66%). Nine patients (28%) achieved a CR, and two patients (6%) achieved a CRp. The median OS was 5.3 months, and the 12-month survival rate was 19%. Fourteen patients (44%) developed an important hyperbilirubinemia, and three patients (9%) had a VOD.
CALGB Group (Stone et al., 2004 ) treated patients with relapsed or refractory AML with HiDARAC associated to GO at different doses (9 or 4.5 mg/m 2 ). The HiDARAC plus GO at 9 mg/m 2 was characterized by a high toxicity; in fact eight of nine treated patients died during induction. Among the 44 following patients treated with HiDARAC plus GO at 4.5 mg/m 2 , seven patients (19%) achieved CR and other two CRp. About 20% of patients presented a liver toxicity, but none presented a VOD. HiDARAC was also combined to topotecan and GO at different doses (6, 4.5 and 2 mg/m 2 ) for the treatment of secondary or relapsed AML (Langston et al., 2004) . Nineteen patients were treated and nine of them (47%) achieved a CR. None experienced VOD or other unexpected toxicities. Chevallier et al. (2005) combined GO (9 mg/m 2 ) with intermediate doses of ara-c and mitoxantrone (MID-AM) in 17 AML patients (13 refractory and four relapsed). A total of 13 patients (76%) resulted responsive: 12 patients (70%) achieved a CR and another one patient achieved a CRp. Four patients presented a grade 3/4 liver toxicity, including a patient who died for VOD. Seven of 13 responder patients relapsed and the median OS and RFS were 11 and 11 months, respectively.
In a more recent study, GO was associated to Bcl-2 antisense (oblimersen) in AML patients in first relapse. Oblimersen was administered at 7 mg/kg/day on days 1-7 and 15-21, whereas GO at the dose of 9 mg/m 2 on days 4 and 18. Among 48 treated patients, 12 showed a response to the treatment (five CR and seven CRp) with a survival among these patients over 6 months. The addition of oblimersen to GO did not cause an increase of serious adverse events (Moore et al., 2006) .
The results of the main studies on GO in relapsed/ refractory patients are reported in Table 2 .
GO in untreated AML
In a report by Estey et al. (2002a) , 51 untreated AML or high-risk MDS patients aged older than 65 years were randomized to receive induction therapy with GO at a dose of 9 mg/m 2 with or without IL-11 at a dose of 15 mg/kg per day on days 3-28. CR was seen in 2/26 Gemtuzumab Ozogamicin and acute myeloid leukemia L Pagano et al (8%) of patients without IL-11 and in 9/25 (36%) with IL-11. Survival was not significantly different in the two groups, 8 and 15 weeks, respectively. However, when compared with historical control treated with idarubicin plus HiDARAC, a high CR rate (48%) and a more prolonged survival was obtained in the control arm. In a following study performed by the same group, 59 de novo AML/MDS patients were treated with the schedule previously used for relapsed/refractory patients (MFAC). This regimen induced a CR in 27 patients (46%) and a CRp in another patient (2%). The median survival period was of 8 months. At 12 months, the survival rate was 38%. The major toxicities were infectious complications, hyperbilirubinemia and raised levels of transaminases. Four patients (7%) developed a VOD (Tsimberidou et al., 2003b) .
The Medical Research Council (MRC) reported the feasibility of combining GO with induction chemotherapy in patients younger than 60 years (AML 15 trial). Seventy-two patients were treated with different chemotherapies (H-DAT schedule or FLAG-Ida schedule) and with escalating doses of GO (from 3 to 9 mg/m 2 ) administered on day 1 of each course (both in induction and consolidation). Patients were stratified into six different cohorts considering induction regimen they received; 91% of those treated with FLAG-Ida or DA (without thioguanine) achieved a CR and 78% of them were RFS at 8 months. Overall 29 patients suffered for 3 and 4 liver toxicity; seven patients suffered for a VOD, also named sinusoidal obstructive syndrome (SOS), that was fatal in three of them; everyone of them had received thioguanine. Other 12 patients died for infectious complication (five aspergillosis and seven bacterial infection) (Kell et al., 2003) .
The interesting results of MRC trials were confirmed in another study by De Angelo et al. (2003) . They treated 53 untreated AML patients with daunorubicin and ara-c, followed by GO (6 mg/m 2 ), obtaining 44 CR (83%). Other 21 patients received a combination of ara-c and GO (6 mg/m 2 ) with nine CR (43%). The EORTC-GIMEMA group recently presented the results of a trial using GO on days 1 and 15 followed by the combination of mitoxantrone, ara-c and etoposide in a cohort of AML elderly patients with either de novo or secondary AML. A total of 57 patients were enrolled. Initial treatment with GO resulted in an overall response rate (13 CR plus seven CRp) of 35% that increased to 54.4% (31/57 patients) with remission induction with combination chemotherapy. However, five patients developed a VOD and four of them died for toxicity. At 226th day, only 12 patients were in continuous CR/ CRp (21%) (Amadori et al., 2004) .
Another study reported the experience in nine elderly AML patients (five untreated AML and four with relapsed/refractory disease) with GO (6 mg/m 2 ) combined with ara-c in continuous infusion. Among only untreated patients, three achieved CR (60%) and two were resistant. The median CR duration was 12 months. The most common adverse event was bleeding; no cases of VOD were observed (Piccaluga et al., 2004b) . Little more wide is the experience of Duke University (Rao et al., 2005) that reported 15 untreated elderly AML treated with HiDARAC plus GO (9 mg/m 2 ). With this schedule the authors obtained an overall response rate of about 67% and an RFS of 6 months.
More recently, on the basis of the positive results of a previous study with GO plus G-CSF priming (Leone et al., 2004) , preliminary data were presented on a series of 23 secondary AML (12 relapsed and 11 newly diagnosed cases): they were treated with G-AraMy combination including rhG-CSF (5 mg/kg, on days 1-8), ara-c as continuous perfusion (100 mg/m 2 on days 4-8) and GO (6 mg/m 2 on day 9). Fourteen patients (61%) achieved a CR, whereas other two patients obtained a PR. The most common adverse event was myelosuppression, as expected. VOD episodes were not recorded. Seven patients (30%) developed a documented infection (including pulmonary aspergillosis in two cases). The median RFS and OS were 6.3 and 7.6 months, respectively (Fianchi et al., 2006) .
Results obtained using GO in combination with other drugs in the induction of first remission for de novo AML are summarized in Table 3 .
GO and acute promyelocytic leukemia
Many reasons make GO an interesting drug in acute promyelocytic leukemia (APL), even in relapsed phase. It resulted highly active because of the large expression of CD33 in APL cells and because of the low levels of P-gp function in leukemic promyelocytes (Guglielmi et al., 1998; Paietta, 2003) . In addition Takeshita et al. (2005) demonstrated that resistance mechanism to GO differ from those reported to explain resistance to alltrans retinoic acid (ATRA) or arsenic trioxide. The efficacy of GO in APL patients was based also on positive results of previous treatment with un-conjugated anti-CD33 monoclonal antibody (HuM195). In fact, in a study on 31 patients with newly diagnosed APL treated with HuM195 twice-weekly for 3 weeks, it was demonstrated that among 22 valuable patients, 12 achieved molecular remission (MR) without additional therapy (Jurcic et al., 2000) .
GO has been successfully used either as a single agent or in combination. The first report by Petti et al. (2001) about a pretreated patient in third hematological relapse who achieved a prolonged CR, prompted investigators to consider GO as a valid alternative in APL. Further single case report showed the efficacy of this approach (Schwarz et al., 2004; Tsimberidou et al., 2004) .
In a study by GIMEMA group (Lo-Coco et al., 2004) , 16 patients relapsed at molecular level were treated with GO at 6 mg/m 2 for two doses. MR was obtained in 14 patients (87%). Of 14 responders, seven remained in sustained MR for a median time of 15 months. A total of six patients showed a liver toxicity but none developed a VOD.
GO has been combined with ATRA in previously untreated patients in a study by Estey et al. (2002b) . Nineteen patients were treated with ATRA until CR with the addition of GO (9 mg/m 2 ) on day 5. Maintenance ATRA and GO were used after achievement of CR. Sixteen patients (84%) achieved a CR, with 14 in a MR, suggesting a benefit of the addition of GO to ATRA. At present, this is the only available study about the GO as front-line therapy in APL; consequently, further studies are needed to prove the major efficacy of the scheme respect to more established associations and anthracycline-based protocols.
At present, no cases of VOD have been reported in APL; it may relate to the GO binding to the high level of CD33 in circulating promyelocytes, which avoids calicheamicin-induced damage of hepatic cells.
Hematological and extrahematological adverse events
The most important GO associated toxicities are myelosuppression and, consequently, febrile neutropenia: infections incidence ranges from 13 to 50% in different series (Amadori et al., 2005; Larson et al., 2005) . Although pluripotent progenitor cells do not express CD33, myelosuppression may be due to the CD33-positivity of more differentiated multipotent hematopoietic cells, targeted by GO. Indeed, thrombocytopenia and neutropenia have been constantly observed after GO-based regimens and they may lead to modify the therapeutic schedule (Sievers et al., 2001) .
Infusion-related adverse reactions (fever, chills, cutaneous rash, hypotension, hypertension, hyperglycemia, dyspnea, nausea, emesis and headache), similarly to other monoclonal antibodies, appear in about 30% of patients at the first infusion of GO, but only in the 10% of them during subsequent administrations (Giles et al., 2001; Larson et al., 2005) . Premedication with acetaminophen and antihistaminics or corticosteroids is effective in reducing these events.
VOD/SOS is the most frequently reported extrahematological adverse event. It is usually defined according to the Seattle and Baltimore criteria, as a coexistence of hyperbilirubinaemia, painful hepatomegaly and fluid retention in the absence of other causes (Bearman, 2000) . Many mechanisms have been proposed to explain the high incidence of hepatotoxicity after GO administration: (1) the damage to the CD33-bearing Kuppfer and sinusoidal cells; (2) the infiltration of the liver by blast cells; (3) the calicheamicin-related damage to sinusoidal cells upon its separation from the antibody. However, even CD33-negative human hepatocytes appeared to metabolize GO, as observed by Cohen et al. (2002) . It is worth noticing that a prior therapy with GO represents an independent risk factor for VOD in patients undergoing HSCT (Wadleigh et al., 2003) .
Investigators associated with the Research on Adverse Drug Events and Reports (RADAR) project reviewed safety reports for GO included in reports of clinical trials and observational studies, interim reports from an FDA mandated Prospective Observational Registry, and the Food and Drug Administration's Adverse Event Reporting System. Medline searches provided incidence estimates of GO-associated VOD/SOS and comparative rates of VOD without GO. VOD is Gemtuzumab Ozogamicin and acute myeloid leukemia L Pagano et al characterized by hyperbilirubinemia, painful hepatomegaly, ascites and sudden weight gain developing at a median of 10 days following GO administration for patients who did not undergo an allogeneic SCT procedure and 13 days following an allogeneic SCT for patients who had previously received GO. Among adult AML patients who received GO in clinical trials, VOD incidence was 3% for GO doses p6 mg/m 2 administered as monotherapy or in combination with non-hepatotoxic agents; conversely it was 28% if GO was administered at 9 mg/m 2 or with thioguanine (McKoy et al., 2006) .
Conclusions
The role of targeted therapy for the treatment of hematological malignancy is continuing to expand as new targets are identified and advances in the conjugation of radioactive molecules and toxins occur. GO activity in relapsed patients has been demonstrated, with approximately 30% of patients achieving a remission: drug allowed equivalent survival and fewer total days of hospitalization than conventional chemotherapy in the same category of patients. Although GO is approved for older patients with relapsed AML who are intolerant of cytotoxic chemotherapy, its potential roles in other settings are actively being studied. At present, cooperative group studies combining GO with standard-dose chemotherapy are ongoing. The Southwest Oncology Group (SWOG) is investigating ara-c and daunorubicin with or without GO followed by HiDARAC followed by either GO or no additional therapy in patients aging 18-55 years with untreated de novo AML (SWOG trial S0106). The Eastern Cooperative Oncology Group (ECOG) is studying daunorubicin dose intensification and GO consolidation therapy before autologous SCT in AML patients (16-60 years). In the Medical Research Council (AML15 trial), patients with AML are randomized to receive induction courses with ara-c, daunorubicin and etoposide; daunorubicin and ara-c or with fludarabine, ara-c, idarubicin and G-CSF, with or without GO on day 1 of course 1. The GIMEMA-EORTC group is conducting a randomized trial (AML-17) employing standard intensive chemotherapy, with or without GO, as induction and consolidation therapy in patients aged 64-75 years with untreated AML. A second trial (AML-19) includes GO monotherapy versus standard supportive care in patients with untreated AML older than 75 years who are not candidates for intensive chemotherapy.
The role of GO before SCT has been investigated in several phase II studies too. In general, prior exposure to GO significantly increases the risk of hepatic VOD in patients undergoing myeloablative allogeneic SCT, but this risk decreases if at least 3 months have elapsed since the last dose of GO (Wadleigh et al., 2003) .
Current data indicate potential role for GO as a component of induction or consolidation regimens in adults and, based on an early study, in the treatment of children with AML. The hepatotoxicity does not appear to be significantly different when GO is used in conjunction with cytotoxic chemotherapy, but the risk of SOS does appear greater when standard dosing schedules are employed in the peritransplant setting. However, GO is well tolerated by most patients.
In conclusion, GO provides an effective and relatively well-tolerated treatment option for patients with CD33-positive AML. It is useful for cytoreduction of the leukemia tumor burden, allowing recovery of normal hematopoiesis. At present, the better dosage seems 6 mg/ m 2 that is characterized by the absence of side effects, particularly VOD. The combination with other antileukemic agents does not increase the toxicity, whereas improves the percentage of response, particularly when it is combined with cytosine arabinoside.
